Current management of hypertrophic cardiomyopathy

@article{Coats2008CurrentMO,
  title={Current management of hypertrophic cardiomyopathy},
  author={Caroline J Coats and Perry M. Elliott},
  journal={Current Treatment Options in Cardiovascular Medicine},
  year={2008},
  volume={10},
  pages={496-504}
}
  • C. Coats, P. Elliott
  • Published 22 November 2008
  • Medicine
  • Current Treatment Options in Cardiovascular Medicine
Opinion statementHypertrophic cardiomyopathy is a heterogeneous clinical syndrome with a wide spectrum of pathophysiologic consequences. Most cases are inherited and caused by sarcomeric protein gene mutations, although phenocopies are often encountered. Genomic research and family studies have improved our recognition of the disease and understanding of its natural history; however, tenuous links exist between genotype and phenotype and thus far have done little to alter clinical management… 
Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.
TLDR
This review provides an historical and personal perspective on the discovery of genetic causes for hypertrophic cardiomyopathy (HCM) and a thematic review series that will present contemporary advances in the field of hypertrophic heart disease.
A REVIEW ON: HYPERTROPHIC CARDIOMYOPATHY
TLDR
The main clinical concerns and therapy options for HCM are summarized in this study.
The genetics of cardiomyopathy: Genotyping and genetic counseling
TLDR
The present and future roles of genetic analysis and counseling in clinical practice and how to assist the transition of genetic screening into current care are assessed to ensure the appropriate practical use of genetic tests in the routine clinical setting are assessed.
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.
TLDR
The effects of pacing in drug-refractory or drug-intolerant hypertrophic cardiomyopathy patients, as well as randomised controlled trials comparing pacing to other therapeutic modalities, are assessed.
Multi-scale computational models of familial hypertrophic cardiomyopathy: genotype to phenotype
TLDR
Multi-scale models that integrate dynamic processes occurring in cardiac cells with properties of myocardial tissue, heart geometry and haemodynamic load in order to predict strain and stress in the ventricular walls and overall pump function have the potential to improve clinical management of FHC through genotype-based risk stratification and personalized therapy.
Genetic Testing for Cardiac Arrhythmias: Ready for Prime Time?
NOVEL MITOCHONDRIAL DNA MUTATIONS ASSOCIATED WITH CHINESE FAMILIAL HYPERTROPHIC CARDIOMYOPATHY
TLDR
The results of the present study imply that mtDNA mutations G7697A, T12477C and G13135A are genetic factors that indicate a susceptibility to HCM and that could be used for the large‐scale screening of genetic markers as well as the early diagnosis of HCM.
Paradoxical Effects of Interatrial Conduction Delay in a Hypertrophic Cardiomyopathy Patient in the Long‐Term: Time is a Great Healer
TLDR
As the interatrial delay reached a critical point, the right and left atrial P‐wave became virtually separated, as demonstrated by the findings of ECGs and echocardiography, and resulted in the complete cessation of tachycardias.
Perhexiline dans le traitement de la cardiomyopathie hypertrophique (hcm)
La presente invention concerne la perhexiline, ou son sel pharmaceutiquement acceptable, destinee a etre utilisee dans le traitement d'une cardiomyopathie hypertrophique (HCM), ainsi qu'une methode
...
...

References

SHOWING 1-10 OF 53 REFERENCES
Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression
TLDR
Current knowledge on the genetics, disease mechanisms, and correlations between phenotype and genotype in patients with HCM are summarized, and the implications of genetic testing in routine clinical practice are discussed.
Hypertrophic cardiomyopathy: a systematic review.
TLDR
An appreciation that HCM, although an important cause of death and disability at all ages, does not invariably convey ominous prognosis and is compatible with normal longevity should dictate a large measure of reassurance for many patients.
Disease-modifying mutations in familial hypertrophic cardiomyopathy: complexity from simplicity.
TLDR
Familial hypertrophic cardiomyopathy is characterized by increased cardiac mass with myocyte and myofibrillar disarray and is associated with electrical instability, which makes it the leading cause of death in young athletes.
Phenotypic diversity in hypertrophic cardiomyopathy.
TLDR
The spectrum of clinical HCM is presented in the context of the genetic heterogeneity of this common human disease and recent progress made in understanding molecular pathways that result in cardiac hypertrophy and the factors that modify these processes are discussed.
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.
...
...